William Russell Miller
#133,054
Most Influential Person Now
William Russell Miller's AcademicInfluence.com Rankings
William Russell Millerphilosophy Degrees
Philosophy
#6574
World Rank
#9630
Historical Rank
Logic
#3721
World Rank
#4919
Historical Rank
William Russell Millerbiology Degrees
Biology
#8914
World Rank
#12055
Historical Rank
Biochemistry
#1319
World Rank
#1439
Historical Rank
Download Badge
Philosophy Biology
William Russell Miller's Degrees
- PhD Biochemistry University of California, Berkeley
- Doctorate Medicine Stanford University
Why Is William Russell Miller Influential?
(Suggest an Edit or Addition)William Russell Miller's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. (2001) (1092)
- A standard curve based method for relative real time PCR data processing (2005) (885)
- Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics (2008) (544)
- Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer (2013) (377)
- The importance of local synthesis of estrogen within the breast (1987) (302)
- Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist (1985) (300)
- Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. (1995) (244)
- ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. (2011) (242)
- The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. (1996) (227)
- Aromatase activity in adipose tissue from breast quadrants: a link with tumour site (1988) (216)
- Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. (2003) (209)
- Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. (2006) (170)
- Significance of aromatase activity in human breast cancer. (1982) (163)
- The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. (2000) (154)
- Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours (2005) (152)
- Aromatase activity in breast tissue (1991) (146)
- The pharmacology of letrozole (2003) (142)
- Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. (2003) (139)
- Oestradiol synthesis from C19 steroids by human breast cancers. (1976) (130)
- Expression of the heat shock protein HSP27 in human ovarian cancer. (1995) (130)
- Molecular response to aromatase inhibitor treatment in primary breast cancer (2007) (129)
- The relationship of cyst type to risk factors for breast cancer and the subsequent development of breast cancer in patients with breast cystic disease. (1985) (129)
- Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer. (1987) (128)
- Relationship between tumour aromatase activity, tumour characteristics and response to therapy (1990) (119)
- Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance (2013) (116)
- Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. (1996) (115)
- p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. (1990) (111)
- Regulation of aromatase activity within the breast (1997) (109)
- Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. (2009) (107)
- Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. (1999) (105)
- Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. (2002) (105)
- The morphological basis of human breast cyst populations (1983) (104)
- Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? (2008) (104)
- The regulation of growth and protein expression by estrogen in vitro: A study of 8 human ovarian carcinoma cell lines (1994) (103)
- ŒSTRADIOL SYNTHESIS BY A HUMAN BREAST CARCINOMA (1974) (102)
- Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole (2007) (100)
- Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors (2001) (99)
- Aromatase inhibitors and breast cancer. (1997) (99)
- Increase in response rate by prolonged treatment with neoadjuvant letrozole (2008) (96)
- Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. (2010) (96)
- A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance (2011) (95)
- Letrozole as Primary Medical Therapy for Locally Advanced and Large Operable Breast Cancer (1998) (94)
- Local endocrine effects of aromatase inhibitors within the breast (2001) (92)
- Classification of human breast cysts according to electrolyte and androgen conjugate composition. (1983) (91)
- Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. (1990) (89)
- Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa. (1994) (84)
- Understanding the mechanisms of aromatase inhibitor resistance (2012) (79)
- A HUMAN TUMOUR MODEL (1986) (78)
- Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole (2010) (76)
- Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. (2002) (76)
- A human tumor model (1986) (76)
- Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. (2003) (76)
- Biological rationale for endocrine therapy in breast cancer. (2004) (75)
- Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole (2006) (75)
- Regulatory Subunits of PKA and Breast Cancer (2002) (75)
- Steroid metabolism by human breast and rat mammary carcinomata. (1974) (75)
- Environmental oestrogens and human reproductive cancers (1998) (72)
- Estrogen and Breast Cancer (1996) (71)
- Expression of oestrogen receptor beta (ERβ1) protein in human breast cancer biopsies (2002) (70)
- Antiaromatase agents: preclinical data and neoadjuvant therapy. (2000) (70)
- Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. (2000) (69)
- The validation of new aromatase monoclonal antibodies for immunohistochemistry—A correlation with biochemical activities in 46 cases of breast cancer (2005) (67)
- Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases. (1987) (67)
- Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. (1994) (65)
- Lessons from the use of aromatase inhibitors in the neoadjuvant setting. (1999) (65)
- Natural history of cystic disease: The importance of cyst type (1985) (65)
- Thrombospondin in malignant and non-malignant breast tissue. (1989) (63)
- Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. (2002) (62)
- Aromatase inhibitors in the treatment of advanced breast cancer. (1989) (58)
- c‐erbb growth‐factor‐receptor proteins in ovarian tumours (1995) (57)
- International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). (2011) (57)
- Analysis of the aromatase cytochrome P450 gene in human breast cancers. (1994) (56)
- Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy (2001) (56)
- Transforming growth factor-beta isoform expression in human ovarian tumours. (1997) (56)
- Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. (2006) (55)
- Endocrine treatment for breast cancers: Biological rationale and current progress (1990) (54)
- Aromatase in skeletal muscle (2003) (54)
- Role of aromatase inhibitors in breast cancer (2005) (52)
- Estrogen receptor alpha positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures. (2006) (52)
- Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes (2003) (51)
- Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole (2010) (51)
- Prognostic significance of oestrogen and progestogen receptor activities in breast cancer (1987) (50)
- Aromatase inhibitors--where are we now? (1996) (48)
- c-erbB-3 protein expression in ovarian tumours. (1995) (48)
- ABC of Breast Diseases: Prognostic Factors (1994) (48)
- The effect of tamoxifen on breast tumour vascularity (2001) (48)
- Hormonal therapy for postmenopausal breast cancer: the science of sequencing (2007) (48)
- Expression of transforming growth factor beta mRNA isoforms in human breast cancer. (1994) (47)
- Aromatase expression in ovarian epithelial cancers (2005) (47)
- Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. (1999) (47)
- Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. (1985) (46)
- Types of cyclic AMP binding proteins in human breast cancers. (1993) (46)
- Oestradiol synthesis by a human breast carcinoma. (1974) (46)
- Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. (1996) (46)
- Contrasting effects of 17 β‐estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo (1993) (45)
- Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. (1991) (45)
- Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. (2005) (44)
- Aromatase and the breast: regulation and clinical aspects. (2006) (44)
- Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. (2004) (44)
- Production and response of human prostate cancer cell lines to granulocyte macrophage‐colony stimulating factor (1994) (44)
- Mitogenic effects of epidermal growth factor and transforming growth factor-alpha on EGF-receptor positive human ovarian carcinoma cell lines. (1992) (43)
- Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report (2003) (43)
- Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast (1998) (42)
- Factors influencing aromatase activity in the breast (1993) (42)
- Paracrine regulation of ovarian cancer by endothelin. (1999) (42)
- Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy. (1996) (40)
- Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment (2006) (40)
- Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer (2002) (40)
- Effect of matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines (1996) (39)
- Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen. (1998) (39)
- An immunohistochemical study of the tissue distribution of the breast cyst fluid protein, zinc alpha2 glycoprotein (1987) (39)
- Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo (1998) (38)
- Estrogens in tissues: Uptake from the peripheral circulation or local production (1987) (37)
- Estrogen regulation of transforming growth factor-α in ovarian cancer (1998) (37)
- Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. (2008) (37)
- Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer (2010) (37)
- Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression (1997) (37)
- The significance of steroid metabolism in human cancer (1990) (37)
- The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer (1997) (37)
- Expression of glutathione S-transferase B1, B2, Mu and Pi in breast cancers and their relationship to oestrogen receptor status. (1989) (37)
- The relative importance of proliferation and cell death in breast cancer growth and response to tamoxifen. (2001) (37)
- Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer (2010) (36)
- Stimulation of human prostate cancer cell lines by factors present in human osteoblast‐like cells but not in bone marrow (1995) (36)
- Changes in messenger RNA expression of protein kinase A regulatory subunit ialpha in breast cancer patients treated with tamoxifen. (1997) (35)
- MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue (2003) (35)
- Metabolism of androgens by human breast tissue. (1973) (35)
- Cyclic AMP binding proteins and prognosis in breast cancer. (1990) (34)
- Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancer: correlations with clinicopathological features. (1996) (34)
- Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines. (1996) (34)
- Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors (2009) (33)
- The H-ras oncogene product p21 and prognosis in human breast cancer (2005) (33)
- An integrated view of aromatase and its inhibition (2003) (33)
- Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer (2004) (33)
- Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial (2008) (32)
- Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues (2002) (32)
- Breast gross cystic disease protein 15 in human breast cancer in culture. (1988) (31)
- Dehydroepiandrosterone sulphate in breast secretions. (1980) (31)
- Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cells. (1992) (30)
- Prospective evaluation of prognostic factors in operable breast cancer. (1996) (29)
- Challenges in defining predictive markers for response to endocrine therapy in breast cancer. (2009) (29)
- Endothelin expression and responsiveness in human ovarian carcinoma cell lines. (1997) (28)
- Growth inhibition by 8-chloro cyclic AMP of human HT29 colorectal and ZR-75-1 breast carcinoma xenografts is associated with selective modulation of protein kinase A isoenzymes. (1995) (28)
- Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cells. (1992) (28)
- p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer (1999) (28)
- Tumour cyclic AMP binding proteins and endocrine responsiveness in patients with inoperable breast cancer. (1987) (28)
- The primary use of endocrine therapies. (1998) (28)
- Aromatase activity and CYP19 gene expression in breast cancers (1996) (27)
- MIB-1 assessments in breast cancers. (2002) (27)
- P-glycoprotein and resistance to tamoxifen (1994) (27)
- Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer (2011) (26)
- Androgen conjugates in human breast cyst fluids. (1982) (26)
- Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer (2002) (26)
- Oestrogen receptor activity and endocrine status in DMBA-induced rat mammary tumours. (1977) (26)
- Extra pituitary actions of LHRH analogues in tissues of the human female and investigation of the existence and function of LHRH-like peptides. (1986) (26)
- Pharmacology of Inhibitors of Estrogen Biosynthesis (1999) (26)
- ERa-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer (2011) (25)
- Aromatase inhibitors: Cellular and molecular effects (2005) (24)
- Endocrine Therapy in Breast Cancer (2002) (24)
- The relevance of local oestrogen metabolism within the breast (1989) (23)
- Predicting response and resistance to endocrine therapy (2008) (23)
- Steroid hormones and cancer: (III) observations from human subjects. (1997) (23)
- Clinical importance of intratumoral aromatase (2004) (23)
- Uptake and synthesis of steroid hormones by the breast (1997) (22)
- Aromatase inhibitors—Gene discovery (2007) (22)
- Is apocrine differentiation in breast carcinoma of prognostic significance? (1990) (21)
- Anti-tumor Effects of Letrozole (2002) (21)
- Pharmacokinetics and metabolism of formestane in breast cancer patients (2001) (21)
- Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice. (1996) (21)
- The identification of C19 steroids in bovine feces. (1956) (21)
- Prostaglandins in human mammary cancer. (1984) (21)
- Risk of breast cancer in women with palpable breast cysts: a prospective study. Edinburgh Breast Group. (1999) (20)
- Androgen metabolism and apocrine differentiation in human breast cancer (2005) (20)
- Reproducibility of microvessel counts in breast cancer specimens (1999) (20)
- Aromatase inhibition and breast cancer (2005) (20)
- Estrogen regulation of transforming growth factor-alpha in ovarian cancer. (1998) (20)
- Factors affecting testosterone metabolism by human breast tissues. (1978) (19)
- Factors affecting dehydroepiandrosterone sulphate levels in human breast secretions (1981) (19)
- Aromatase inhibitors: prediction of response and nature of resistance (2010) (19)
- Hormonal Correlates of Apocrine Secretion in the Breast a (1986) (19)
- Using biological measurements, can patients with benign breast disease who are at high risk for breast cancer be identified? (1992) (19)
- Conjugation, Distribution, and Biological Half-Life (t ½) of Radioactive Progesterone in Plasma and Red Cells of Bovine Blood, (1963) (19)
- Zinc alpha-2 glycoprotein levels in serum and breast fluids: a potential marker of apocrine activity. (1991) (18)
- Relation between apocrine differentiation and receptor status, prognosis and hormonal response in breast cancer. (1990) (18)
- Fundamental research leading to improved endocrine therapy for breast cancer. (1987) (18)
- Inhibition of transforming growth factor α (TGF-α)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868 (1999) (17)
- Steroid hormones and cancer: (II) lessons from experimental system (1997) (17)
- Outcome after extended follow-up in a prospective study of operable breast cancer: key factors and a prognostic index (2002) (17)
- Oestrogens and breast cancer: biological considerations. (1991) (17)
- Hormonal factors and risk of breast cancer. (1993) (17)
- Characterization of the aryl hydrocarbon receptor and aryl hydrocarbon responsiveness in human ovarian carcinoma cell lines. (1993) (16)
- Estrone and estradiol metabolism in vivo in human breast cysts☆ 1 1 ☆ A preliminary report was presented at the 45th Annual Meeting of the Society for Gynecologic Investigation, March 11–14, 1998, Atlanta, Georgia - abstract 185. (2000) (16)
- Analysis of cAMP RI alpha mRNA expression in breast cancer: evaluation of quantitative polymerase chain reaction for routine use. (1996) (15)
- Prostaglandins and prognosis in human breast cancer. (1987) (15)
- Steroid metabolism and oestrogen receptors in human breast carcinomas. (1981) (15)
- Pathways of Hormone Metabolism in Normal and Nonneoplastic Breast Tissue (1990) (14)
- Expression of enzymes of covalent protein modification during regulated and dysregulated proliferation of mammary epithelial cells: PKA, PKC and NMT. (1999) (14)
- Cyclic AMP binding proteins in human breast cancer. (1985) (14)
- Quantification of epidermal growth factor in human breast cyst fluids: Correlation with dehydroepiandrosterone‐sulphate and electrolyte concentrations (1989) (13)
- Angiogenesis and breast cancer (1998) (13)
- Tamoxifen increases apoptosis but does not influence markers of proliferation in an MCF-7 xenograft model of breast cancer. (2000) (13)
- Molecular effects of oestrogen deprivation in breast cancer (2011) (12)
- Cyclic adenosine 3',5'-monophosphate binding proteins in human colorectal cancer and mucosa. (1991) (12)
- Platelet-associated proteins in human breast cyst fluids. (1985) (11)
- Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole (2005) (11)
- Lectin binding and steroid receptors in human breast carcinomas (1985) (11)
- Binding of [3H]-methyltrienolone (R1881) by human breast cancers. (1983) (11)
- Biology of Female Cancers (1997) (11)
- An analysis of the content and morphology of human breast microcysts. (1985) (11)
- Background and development of aromatase inhibitors (2008) (11)
- Identification and mechanisms of endocrine resistance (2008) (11)
- Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. (2011) (10)
- Mammary steroidogenesis: therapeutic implications. (1987) (10)
- Antitumour activity and schedule dependency of 8-chloroadenosine-3',5'-monophosphate (8-ClcAMP) against human tumour xenografts. (1998) (10)
- Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience. (2005) (10)
- Steroid Hormones in Breast Cyst Fluids (1990) (10)
- Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference (2008) (10)
- Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients (2012) (10)
- BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland. (1997) (10)
- Milk protein concentrations in the mammary secretions of non-lactating women. (1981) (10)
- Neoadjuvant endocrine therapy models. (2006) (10)
- Aromatase inhibition: determinants of response and resistance (1995) (10)
- Biosynthesis of steroids from pregnenolone-16-3H by bovine ovarian tissue in vitro☆☆☆ (1963) (9)
- Steroid hormones and cancer: (II) Lessons from experimental systems. (1997) (9)
- Pilot studies on the p53 gene in nipple aspirate fluid from patients with breast cancer (2000) (9)
- The mutagenic activity of human breast secretions (2005) (9)
- BREAST CANCER: Hormonal factors and risk of breast cancer (1993) (9)
- Biological signalling and the mammary gland (1997) (9)
- Protein concentrations in fluid from gross cystic disease of the breast. (1984) (9)
- Hyperprolactinemia and steroid metabolism by rat mammary adenocarcinomas. (1976) (8)
- ŒSTROGEN IN BREAST FLUID (1977) (8)
- S1-8: Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen. (2011) (8)
- Variations in steroid receptors and cyclic AMP binding proteins across human breast cancers: evidence for heterogeneity. (1986) (8)
- Factors influencing the response of MCF-7 cells to an agonist of luteinising hormone-releasing hormone. (1991) (8)
- Nipple aspirate fluid in relation to breast cancer. (1999) (8)
- Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer (2015) (8)
- Proceedings: Factors affecting oestrogen synthesis in human breast. (1976) (7)
- Controversies in Breast Cancer 2010 (2010) (7)
- Prognostic factors in breast cancer. (1992) (7)
- In vitro effects of oestrogen on 5alpha reduction of testosterone in hormone-dependent rat mammary carcinomata. (1976) (7)
- In vitro effects of prolactin upon testosterone metabolism by rat mammary adenocarcinomata. (1976) (7)
- Surgical issues surrounding use of aromatase inhibitors (2005) (7)
- Molecular characterisation of ER+ breast cancer before and during treatment with the aromatase inhibitors, letrozole and anastrozole (2005) (7)
- Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in vivo . (1994) (7)
- Genes Discriminating between Breast Cancers Responsive or Resistant to the Aromatase Inhibitor, Letrozole (2010) (7)
- 0-12. Qualitative effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast (1997) (7)
- Effects of serial passage on the endocrine response and steroid metabolism of a rat mammary carcinoma. (1980) (6)
- Oestrogen in breast fluid. (1977) (6)
- Oestrogen receptors in transplantable ovary-independent, mammary tumours of the rat. (1978) (6)
- Characterisation and properties of a small cell lung cancer cell line and xenograft WX322 with marked sensitivity to alpha-interferon. (1991) (6)
- Breast cancer risk with cyst type in cystic disease of the breast (1997) (6)
- Aromatase and its inhibitors: new biology and clinical perspectives. (1999) (6)
- Oral contraceptive steroids and breast secretions (1989) (6)
- Oestrogen receptor beta and neoadjuvant therapy with tamoxifen (2016) (6)
- Oestrogen in breast fluid. (Letter) (1977) (6)
- ANDROGEN METABOLISM IN GYNAECOMASTIC BREAST TISSUE (1974) (5)
- The Fractionation and Purification of Extracts Containing the Androgenic Factor of Cow Feces (1953) (5)
- Aminoglutethimide and advanced breast cancer [proceedings]. (1980) (5)
- Hormonal status and testosterone metabolism of DMBA-induced rat mammary carcinomas. (1976) (5)
- Controversies in Breast Cancer 2008 (2008) (5)
- Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers (2017) (5)
- ERBB2 status and outcome of endocrine treatment. (2008) (5)
- Bridging the gap between translational research and clinical application. (2011) (5)
- Letrozole (femara) is a more effective inhibitor of estrogen activity than tamoxifen: Evidence from a randomized phase III trial of 4 months preoperative endocrine therapy for postmenopausal women with primary invasive breast cancer (2001) (5)
- Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancers. (1994) (5)
- Cyclic AMP-dependent protein kinase in rat mammary tissue: expression of catalytic and regulatory subunits throughout pregnancy and lactation. (1994) (5)
- The Extraction and Hydrolysis of the Androgens of Cow Manure (1951) (5)
- Effect of Pregnenolone, Progesterone, and Derived Metabolites on Mammary Gland Growth in Rats.∗ (1961) (5)
- Morphological and biological observations relating to the development and progression of breast cancer. (1994) (5)
- Cell-cycle complete response after neoadjuvant letrozole predicts superior relapse-free and overall survival: Long-term follow- up of the letrozole P024 study (2007) (5)
- Human ovarian cancer cells: interaction with Tetrachlorodibenzo-p-dioxin (TCDD) (1992) (5)
- Urokinase and tissue-type plasminogen activators are present in breast cyst fluids. (1988) (4)
- pH of human breast cyst fluids. (1984) (4)
- Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy (1996) (4)
- Plasma oestrogens and oestrogen receptors in breast cancer patients. (1985) (4)
- Evidence for in Vivo Conversion of C21 Steroids to C19 Androgens in the Bovine (1961) (4)
- Risk factors for breast cancer (1995) (4)
- BREAST CANCER Hormonal factors and risk of breast cancer (1993) (4)
- Urinary etiocholanolone and prognosis in early carcinoma of the breast (1978) (4)
- Mutagens in human breast cyst fluid (2005) (4)
- MIB-1 in relation to tumour response and survival in patients with breast cancer treated with primary systemic therapy (1999) (4)
- Uptake of dehydroepiandrosterone sulphate into human breast cyst fluids (1997) (4)
- Estrogen-independent cell proliferation occurs in the majority of estrogen receptor positive (ER+)/HER2 gene-amplified primary breast cancers: Evidence from a combined analysis of two independent neoadjuvant letrozole studies (2005) (4)
- Protein-kinase A and human disease: The core of cAMP-dependent signaling in health and disease (2002) (3)
- Levels of androgen conjugates and oestrone sulphate in patients with breast cysts. (1990) (3)
- Sex-hormone-binding globulin and oestrogen receptors. (1981) (3)
- Neoadjuvant endocrine therapy of breast cancer (2002) (3)
- 405 Androgen receptors in human breast cancers (1983) (3)
- BREAST CANCER IN WOMEN WITH PALPABLE BREAST CYSTS. AUTHORS' REPLY (1999) (3)
- 5 Endogenous Sex Hormones in Cancer Development (1988) (3)
- Growth-control of human ovarian-carcinoma cells by insulin-like growth-factors. (1995) (3)
- Aromatase 2004, Edinburgh, UK, 6-8 September 2004 (2004) (3)
- Interactions Between Malignant and Non-Malignant Components of the Breast (1992) (3)
- Expression of the Heat Shock Protein H5P27 in Human Ovarian Cancer (1995) (3)
- LHRH agonists and human breast cancer cells (1987) (3)
- Do classical oestrogen markers predict for clinical response to endocrine therapy? (2007) (3)
- Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer (2013) (3)
- Preface: controversies in breast cancer (2007) (3)
- Correlation of Immunohistochemistry (IHC) and gene microarray analysis of breast biopsies from a preoperative endocrine therapy trial (2001) (2)
- Hormonal status and steroid metabolism in two transplantable rat mammary tumours. (1979) (2)
- Using changes in gene expression as assessed by microarray analysis of sequential tumour biopsies to predict response to neoadjuvant therapy with letrozole (2006) (2)
- Changes in proliferation in breast cancer with tamoxifen and correlation with tumour response (2001) (2)
- Hydrolysis, Extraction, and Fractionation of the Biliary Androgens in the Female Bovine (1961) (2)
- 0-75. Letrozole as primary medical therapy for locally advanced breast cancer (1997) (2)
- Biochemistry of Cyst Fluids and its Relevance (1990) (2)
- Tumour steroid hormone synthesis and estrogen receptor status in breast cancer patients (1981) (2)
- 17β Hydroxysteroid dehydrogenase activity in breast adipose tissue from breast cancer patients (1987) (2)
- Markers of sensitivity, dependence and resistance to endocrine therapy for breast cancer (2011) (2)
- Is cancer in women preventable by hormone manipulation? (1991) (2)
- Reply: Expression of oestrogen receptor beta proteins in human breast cancer biopsies (2002) (2)
- Expression and distribution of TGFβ mRNA isoforms in a small group of human breast cancers examined by in situ hybridization (1995) (2)
- Patterns of cyclic AMP binding in normal human breast (2004) (2)
- Tumour aromatase as measured by immunohistochemistry in patients treated neoadjuvantly with either letrozole or tamoxifen in the P024 randomised trial—correlations with other biomarkers (2006) (2)
- In vitro effects of oestrogen on testosterone metabolism by human breast cancers. (1978) (1)
- Molecular endocrinology and breast cancer – A reed before the wind lives on (a tribute to Professor Mike Reed) (2011) (1)
- Neoadjuvant tamoxifen and aromatase inhibitors (2003) (1)
- Prostaglandins andprognosis inhumanbreast cancer (1987) (1)
- Expression of PK-A catalytic subunit in mammary tissue during pregnancy and lactation. (1993) (1)
- 0-9. Tamoxifen alters the relationship between bcl-2 and apoptosis in breast cancer (1997) (1)
- Understanding the mechanisms of aromatase inhibitor resistance (2012) (1)
- Evaluation of long term recurrence rate following breast conserving surgery after neoadjuvant endocrine therapy (2001) (1)
- Steroid Metabolism and Oestrogen Receptors in Human Breast Carcinomas (1982) (1)
- Patterns of protein phosphorylation in membrane fractions from normal breast (1994) (1)
- 12-O-tetradecanoylphorbol 13-acetate induced differentiation in human lung squamous carcinoma cells. (1992) (1)
- Insulin-Like (IGF-I, IGF-II), Epidermal (EGF) and Alpha Transforming (TGF-α) Growth Factors in Human Breast Cyst Fluid (BCF) (1993) (1)
- Cellularity and the quantitation of estrogen receptors (1982) (1)
- Progestogen and oestrogen receptor activity in ovary-dependent and ovary-independent tumours of the rat. (1981) (1)
- Intra-Mammary Steroid Transformation: Implications for Tumorigenesis and Natural Progression (1989) (1)
- Effects of letrozole and anastrozole on ductal carcinoma in situ (DCIS): results from a randomised trial (2006) (1)
- Estradiol (E) and estrone (E) metabolism in human breast cysts (1998) (1)
- Steroid hormones and cancer: (I) basic biology and endocrinology. (1996) (1)
- Steroid interconversions by metastatic deposits of a human bronchogenic carcinoma. (1976) (1)
- Does breast cyst type predict for breast cancer risk? A question still to answer (1988) (1)
- Testosterone metabolism by breast tumours. (1972) (1)
- Early Acquired Resistance to Endocrine Therapy: Extending the Neoadjuvant Model. (2009) (1)
- 100. Changes in TGFB mRNA expression in breast cancer patients treated with tamoxifen (1995) (1)
- Steriod metabolism by human normal thyroid, nodular goitre and thyroid cancer. (1974) (1)
- Controversies in Breast Cancer 2009 (2009) (1)
- Carcinoembryonic antigen (CEA) in explants of human breast cancer: comparison of immunohistochemical detection and release during short-term culture. (1983) (1)
- Factors affecting oestrogen synthesis in human breast. (Abstract only) (1976) (1)
- Expression of TGFβ isoforms in breast cancer (1994) (1)
- A review of aromatase inhibitors used for neoadjuvant endocrine therapy (2001) (1)
- Ca(2+)-dependent and Ca(2+)-independent protein kinase C activity in human breast biopsies. (1995) (1)
- PLASMA SEX HORMONE BINDING GLOBULIN AND TUMOUR OESTROGEN RECEPTOR STATUS IN BREAST CANCER PATIENTS (1981) (1)
- The cyclic adenosine 3',5' monophosphate-dependent protein kinase system in breast cancer (1995) (1)
- Patterns of protein breast phosphorylation in membrane fractions from normal (1994) (1)
- [Aromatase and breast cancer]. (2001) (1)
- Prediction of Response to Aromatase Inhibitors in Breast Cancer (2015) (1)
- Induction of tumour aromatase following treatment with aminoglutethimide-hydrocortisone in patients with breast cancer (1987) (1)
- New drugs in breast cancer (2001) (1)
- Effects of aminoglutethimide and 4-hydroxyandrostenedione on in vitro aromatization by human breast cancers [Poster 42] (1987) (1)
- Effects of Prolactin upon C19 Steroid Metabolism by Rat Mammary Carcinoma (1974) (1)
- Introduction to the cell and molecular biology of cancer (1997) (1)
- Production of IL-6 and expression of cytokine receptors by ovarian cancer cell lines. (1993) (0)
- 12-0-Tetradecanoylphorbol 13-acetate induced differentiation inhuman lung squamous carcinoma cells (1992) (0)
- Transforming growth factor-mRNA expression and growth control of human ovarian carcinoma cells (2007) (0)
- Transforming growth factor-P mRNA expression andgrowth control of humanovarian carcinoma cells (1992) (0)
- A pilot study of the use of p53 gene mutations as a biochemical marker for bladder cancer in bladder washing samples (1997) (0)
- The biochemistry of cyst fluids. (1989) (0)
- 103 P - Induction of expression of tumour TGFβ2 MRNA is associated with response to tamoxifen in breast cancer (1996) (0)
- CYP19 GENE RESEQUENCING AND GENOTYPE DRUG RESPONSE-PHENOTYPE ASSOCIATION IN BREAST CANCER TREATED WITH NEOADJUVANT AROMATASE INHIBITORS. (2010) (0)
- Short communication Identification and mechanisms of endocrine resistance (2017) (0)
- Advanced Breast Cancer (2002) (0)
- Early Assessment of Proliferation by the Genomic Grade Index (GGI) Predicts Response to Neo-Adjuvant Letrozole (2009) (0)
- Steroidogenesis in human breast cancer, benign breast disease and normal breast tissue (1973) (0)
- Expression of PK-A catalytic and regulatory subunits in lactating rat mammary tissue: effects of litter removal. (1995) (0)
- 0-49. Relationship between tamoxifen duration and endometrial thickness (1997) (0)
- Early Breast Cancer (2002) (0)
- Correlation of protein kinase A and protein kinase C activities in normal breast tissue (1998) (0)
- Introduction to sessions on Personalising treatment (2007) (0)
- FOR TUMORIGENESIS AND NATURAL PROGRESSION (1989) (0)
- Proceedings: The effects of fentazin on androgen metabolism in DMBA induced rat adenocarcinomata. (1974) (0)
- oral-cancer-screening-01 (2010) (0)
- Protein kinase C does not acutely modulate protein kinase A activity in mammary gland acini prepared from mid-pregnant and mid-lactating rats. (1996) (0)
- Direct Effects of LHRH and Agonists on Human Breast Cancer Cells (1986) (0)
- Edinburgh 12-0-Tetradecanoyl phorbol-13-acetate induced differentiation in human lung squamous carcinoma cells. (2007) (0)
- Proceedings: Endocrine status and steroid metabolism in a transplanted rat mammary carcinoma. (1976) (0)
- DIFFERENTIAL EFFECTS OF THE BPH DRUG, PERMIXON [R], ON CELLS FROM VARIOUS TISSUES (1999) (0)
- Effects of drugs associated with hyperprolactinemia on plasma steroids and on steroid receptors and metabolism in human breast cancer (2005) (0)
- Absence of mutations in sites of key functional importance of the RIα and RIIβ regulatory subunits of protein kinase A in human breast cancers (1998) (0)
- Abstract P4-02-02: Epidermal Growth Factor Receptors (ErbB/HER) and the Ligand Neuregulin 1 (NRG1) Increase in Breast Tumors during Short Time Endocrine Treatment (2010) (0)
- Growthinhibition observed following administration ofan LHRH agonist toa clonal variant oftheMCF-7breast cancercell line isaccompanied byan accumulation ofcells intheGO/Giphase ofthecell cycle. (1991) (0)
- Androgen metabolism in human neoplastic and normal breast tissue. (1973) (0)
- Comparison of methods of assessing apocrine differentiation in breast carcinoma (1989) (0)
- Androgen metabolism in human neoplastic and normal breast tissue (1973) (0)
- Explorer Functional Genetic Polymorphisms in the Aromatase Gene CYP 19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors (2017) (0)
- LHRH binding sites in human primary breast tumours (1990) (0)
- 0-7. Risk of breast cancer in cystic disease of the breast (1997) (0)
- O-45 Reproducibility and interpretation of quantitative gene expression measurements in breast cancer biopsies (2007) (0)
- Miller and Sharpe : Environmental oestrogens and cancer 96 (0)
- Flow cytometry and the measurement of proliferative indices and PS2 expression in breast cancer (1992) (0)
- Prostaglandins inhumanmammary cancer (1984) (0)
- Studies relating to the breast, its tumours and fluids (1988) (0)
- Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer (2015) (0)
- Membrane-Bound (MB) Catechol-O-Methyltransferase (COMT) Genetic Polymorphisms, Catechol Estrogen Conjugation and Breast Cancer Risk Reduction (2008) (0)
- Aromatase inhibitors and breast cancer. (2006) (0)
- Discussion: session 3. Policy issues in applying epidemiologic evidence* (1981) (0)
- Introduction to session on undue and disproportionate influences (2010) (0)
- University of Rochester--leaders in heavy metals. (1993) (0)
- Direct inhibition of human breast cancer cells by an LHRH agonist (1986) (0)
- The effect of ocestrogen on steroid metabolism by rat mammary carcinomas. (1975) (0)
- Development and Validation of a Method for Using Breast Core Needle Biopsies for Gene Expression Microarray Analyses 1 (2002) (0)
- Effects of aromatase inhibitors on breast cancer (2002) (0)
- 822 Stobhill lung cancer support service (1997) (0)
- Flow cytometric detection of P-glycoprotein (P-G) in sequential fine needle aspirates (FNA) from patients receiving primary chemotherapy for operable breast cancer (1992) (0)
- Computational inference of gene expression signatures differentiating between breast cancers responsive or resistant to letrozole. (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With William Russell Miller?
William Russell Miller is affiliated with the following schools:
